What is QV Bioelectronics?
QV Bioelectronics is a pioneering medical technology firm dedicated to the development of implantable bioelectronic therapies. The company focuses on the treatment of aggressive cancers, with a primary emphasis on brain tumors. Its core innovation involves the delivery of targeted electric field therapy via specialized implantable devices. These devices are engineered to disrupt the division of cancer cells while preserving the integrity of surrounding healthy tissue. By enabling continuous, localized treatment, the company offers a sophisticated alternative to traditional systemic therapies, aiming to improve patient outcomes and quality of life through precision engineering and advanced clinical application.
How much funding has QV Bioelectronics raised?
QV Bioelectronics has raised a total of $7.8M across 2 funding rounds:
Other Financing Round
$2.5M
Grant
$5.4M
Other Financing Round (2023): $2.5M with participation from Science Angel Syndicate, Northern Gritstone, Catapult Ventures, and Fink Family Law Offices
Grant (2026): $5.4M led by GM&C Life Sciences Fund, NIHR, Empirical Ventures, and UK Research & Innovation
Key Investors in QV Bioelectronics
GM&C Life Sciences Fund
A venture capital firm focused on seed and early-stage investments in life sciences and growth opportunities across the UK, specifically supporting innovation in the Greater Manchester and Cheshire regions.
NIHR
A government-backed agency that funds research into health and care, partnering with the NHS and academic institutions to transform healthcare and advance scientific discovery.
Empirical Ventures
A specialist venture capital firm that combines deep scientific expertise with financial backing to support early-stage, deep-tech ventures in sectors including Life Sciences and TechBio.
What's next for QV Bioelectronics?
With the support of this major enterprise-level funding, QV Bioelectronics is poised to transition into a more intensive phase of clinical development and operational scaling. The strategic roadmap likely includes the expansion of its research and development capabilities, the initiation of further clinical trials, and the refinement of its implantable device architecture to meet regulatory standards. As the company continues to bridge the gap between deep-tech innovation and clinical practice, the focus will remain on validating the efficacy of its electric field therapy in human subjects. This capital provides the necessary runway to navigate the complex regulatory landscape of medical devices while fostering partnerships with leading oncology centers to ensure the successful integration of its technology into standard care protocols.
See full QV Bioelectronics company page
